The business plan outlines an opportunity in the US healthcare market for point-of-care diagnostic solutions. Specifically, it aims to develop a biosensor using cytochrome P450 enzymes to enable quick diagnosis and drug monitoring. This would help address delays in prognosis and high costs associated with traditional lab tests. The plan is to launch solutions first for clinical trials and blood analysis, followed by urine analysis. Financial projections estimate capturing 3-5% of relevant markets by 2017 and achieving profitability, with research and development comprising 20% of expenses as new solutions are developed to address pain points in geriatric care and diagnostics.

1. Business Plan
CANASITA
Enabling Bioscience Processors

2. USA IVD Market Opportunity: $35 Billion
Source: Yole Development Market Research Report (Sep, 2012)
USA Elderly Population:
 40 Million aged 65 or older
 88 Million aged 65 or older by 2050
USA Affordable Care Act (2014):
 30 Million newly covered patients
$900 Million (2017)

3. A. Geriatrics Care: Nursing Homes & Assisted Living
B. POC Diagnostics: State of Health Panel Test
Pain Point:
 Delayed Prognosis:
Slow turnaround time (12/24hrs) from Blood Samples to Results
 Cost & Inconvenience:
Multiple Visits to Doctors, Specialists & Labs.
Laboratory Specialists, Complex Equipment & High CapEx.
POC Opportunity in Healthcare

4. Cytochrome (CYP) P450 Biosensor:
 CYP enzymes and transporters, have profound effects on the activity and
expression and therefore also the final biological activity, efficacy and safety of
drugs.
 90% of marketed drugs are metabolized by only five CYP isoforms (CYP1A2,
CYP2C9, CYP2C19, CYP2D6, CYP3A4/5)
Pain Point:
 Cost & Time: Currently-available methods (GC, HPLC, MS) used for in vitro
quantifying the levels of drugs in biological fluids are time-consuming, require
complex instruments and expensive ($300/patient).
 Limitations: Cannot measure plasma concentrations of drugs or their metabolites
during pharmacological cure. Ex: Transplant Patients
POC Opportunity: Clinical Trials & Drug Monitoring

5.  Simple & Elegant POC Solution.
 Fully Integrated Microfluidic Processor Platform
 Nano-Particle Based Cell Detection & Quantification
 Low-Cost Point-of-Care Diagnostic Instrument
 CLIA Waiver.
Canasita Solution

6. Canasita: Revenue & Business Plan
Note:
1. Assumes Tax Rate of 35%
2. COGS include licensing and royalty payments where applicable
3. R&D Costs include cost of Clinical Trials where applicable

7. 5-Year Goals:
 Year-2/Year-3: Solution for Clinical Trials Market
 Year-3/Year-4: Solution for Blood Analysis Market
 Year-4/Year-5: Solution for Urine Analysis Market
Market Share Goals (FY-2017):
 3% - 5% : Urine Analysis Market.
 3% - 5% : Blood Analysis Market
 5%: Clinical Trials Market
Financial Targets (FY-2017):
 COGS: 45%
 R&D: 20%
 SG&A: 15%
5-Year Goals and Objectives